Introduction
For patients with multiple myeloma, the standard of care after myeloablative chemotherapy and reinfusion of autologous PBSCs is the initiation of growth factors (typically filgrastim) on day 5, continuing the agent daily until a neutrophil count of 500/mL has been achieved for three consecutive days. 1 The value of filgrastim in this setting has been established by multiple prospective randomized studies performed 20 years ago. [2] [3] [4] Since these studies were published establishing the value of growth factors, several important changes have occurred in SCT methods. PBSCs are now used preferentially over autologous BM because of the more rapid engraftment and ease of procurement of CD34 þ cells. 5 In addition, use of prophylactic antibiotics for prevention of infection in transplant patients is much more effective, with the introduction of fluoroquinolone antibiotics, triazole antifungal agents and antiviral guanosine nucleoside analogs. 6 The latest recommendations for the use of WBC growth factors continue to endorse their use in this setting. 7 Complications after the administration of granulocyte hematopoietic growth factors are rare, but acute respiratory distress syndrome 8 has been reported, as have allergic-type reactions 9 including dyspnea, wheezing and hypotension. Alveolar hemorrhages have been reported, and the engraftment syndrome, 10 related to a rapid increase in the leukocyte count, may occur. 11 Splenic rupture, including rare fatal cases, has been reported; 12 bone pain is seen in approximately one-fourth of patients, 13 as is cutaneous vasculitis. 14 Previously, in our autologous stem cell program, the use of growth factor after SCT for amyloidosis was discontinued; this did not result in an increase in bacteremia or hospital days, although a minimal delay in leukocyte recovery was seen. 15 On the basis of these observations, the transplant group at Mayo Clinic, Rochester, MN, USA, made a policy change to discontinue the use of filgrastim as part of the supportive care guidelines after stem cell infusion in patients with multiple myeloma receiving myeloablative chemotherapy. Here, we report the outcomes in a large cohort of patients who received no posttransplant growth factor and compare them with those of patients who received traditional filgrastim with otherwise identical supportive care guidelines. The key end points were engraftment, hospitalization and frequency of bacteremia.
Patients and methods
Patients with multiple myeloma treated at Mayo Clinic are prospectively enrolled in a database that includes relevant demographic, clinical and laboratory characteristics and is continuously updated. This database was searched for the records of all consecutive patients with multiple myeloma undergoing SCT from 1 April 2003 through 31 December 2009. These dates were selected to encompass a period when the techniques for apheresis, 16 stem cell cryopreservation, cell thawing and reinfusion remained unchanged. In addition, antibiotic prophylaxis and criteria for hospitalization did not change during this period. No patients were excluded and no patients were lost to follow-up. All patients gave written consent in accordance with Minnesota laws, Mayo Clinic Institutional Review Board regulations and appropriate federal regulations. The Mayo Clinic Institutional Review Board approved the study.
All patients received conditioning chemotherapy and stem cell infusions as outpatients. All patients who received SCT had a minimum of 2 Â 10 6 CD34 þ cells/kg. Apheresis was performed by processing 11-14 L of blood in 4 h. Engraftment was calculated from day 0 of the SCT. Neutrophil engraftment required a sustained count of 500 neutrophils/mL. Engraftment of platelets required a count of 50 000 platelets/mL (untransfused), with no platelet transfusions within the preceding 48 h. For example, if platelets were given for a platelet count of 20 000/mL, and the platelet counts on two of the subsequent days were 55 000 and 60 000/mL, the day with a count of 55 000/mL could not be designated as the day of engraftment because of the potential incremental effect of the transfusion. Data on patients who died before engraftment were censored on the date of death; all patients with failed engraftment are included in the analysis.
All patients were considered evaluable for bacteremia and duration of hospitalization. Bacteremia was defined as the presence of a positive blood culture at any time during the transplant course. Surveillance blood cultures were obtained of patients after catheter placement. This practice was discontinued at the end of 2007. After a finding of positive blood culture, no attempt was made to distinguish contamination from true bacteremia. In this immuneincompetent population, positive blood cultures due to Micrococcus or Corynebacterium were considered bacteremia. Criteria for hospital admission included intractable mucositis, dehydration and a decrease in performance status. Persistent neutropenic fever in an otherwise stable ambulatory patient was not a criterion for hospitalization.
Statistical analysis was performed by the first author (MAG) using JMP statistical software (SAS Institute, Inc, Cary, North Carolina). The Kaplan-Meier method was used for the analysis of time to engraftment and duration of hospitalization. Group differences were analyzed for continuous variables using Kruskal-Wallis rank-sum testing. Differences in discrete variables were compared between groups using the Fisher exact test, and all probabilities were two-tailed. Po0.05 was considered significant.
Results
During the study period, 664 consecutive patients received SCT: 498 patients who were treated through March 2008 who received standard filgrastim and 166 patients who were treated beginning April 2008 who received no growth factors. Patient characteristics are shown in Table 1 . The groups were similar in most characteristics; the proportion of patients with stage III myeloma was the same in both groups. However, patients who did not receive filgrastim had a lower serum albumin level (Po0.001) and a slightly lower serum creatinine value (P ¼ 0.002). The primary reason for the difference in proportions of stage I and II disease between the groups seems to be the lower albumin level in the patients not given filgrastim. The infused CD34 þ cell count on day 0 also was significantly lower for patients not given filgrastim Neutrophil engraftment was achieved at a median of 12.5 days post transplant in patients receiving filgrastim, compared with 13.5 days for the group that did not receive filgrastim (log-rank Po0.001) (Figure 1 ). Only 1 of the 664 patients died before neutrophil engraftment. In the filgrastim group, 90% of patients had engraftment by day 14.5; in the no-filgrastim group, 90% had engraftment at day 17.5. Engraftment of 50 000 platelets/mL occurred at a median of 14.5 days in both groups (log-rank P ¼ 0.12) (Figure 2 ). Nine patients (1.4%) died before platelet engraftment and their observations were censored. Engraftment of 50 000 platelets/mL was achieved by day 25 in 90% of patients receiving filgrastim; in the no-filgrastim group, 90% had engraftment by day 21 (P ¼ 0.12). In an analysis of outcomes on the basis of number of CD34 þ cells transfused, patients who had an infusion of less than 3 Â 10 6 CD34 þ cells/kg had significantly slower platelet engraftment than those infused with greater than that number (17.5 vs 14.5 days; P ¼ 0.003) and slower neutrophil engraftment (14.5 vs 12.5 days; P ¼ 0.047). In our cohort, however, only 27 of 645 patients (4%) had an infusion of less than 3 Â 10 6 CD34 þ cells/kg. Hospitalization of patients is shown in Figure 3 . In patients who received filgrastim, 38% were never hospitalized, and the median duration of hospitalization was 3.5 days. In the no-filgrastim group, 52% were never hospitalized and the median duration of hospitalization was 0 days. In this analysis, however, the mean number of hospital days-4.1 days for the no-filgrastim group and 7.0 days for the filgrastim group (Po0.001)-is a better reflection of the total utilization of hospital resources.
Comparison of the incidence of bacteremia between the two groups showed a significantly higher frequency of positive blood cultures among the filgrastim group (195 of 496, 39%) than among the no-filgrastim group (45 of 165, 27%) (P ¼ 0.005). However, policies for blood cultures differed over these two time periods. In the earlier part of the study period, while patients were still receiving filgrastim, surveillance blood cultures were obtained immediately after line placement; surveillance blood cultures were not routinely obtained later in the study for patients not receiving filgrastim. When coagulase-negative Staphylococcus bacteremia was excluded from the analysis, bacteremia was seen in 42 of 343 patients receiving filgrastim (12.2%) and in 21 of 141 patients not receiving filgrastim (14.9%) (P ¼ 0.46). If positive blood cultures obtained on or before day 0 were excluded, posttransplant bacteremia was seen in 116 patients (23.3%) in the filgrastim group and 42 patients (25.3%) in the nofilgrastim group (P ¼ 0.60).
To assess the effects of bacteremia on recovery of neutrophils and platelets in all patients, we compared time to engraftment between patients with (n ¼ 240) and without (n ¼ 421) bacteremia. Time to recovery of neutrophils was not affected by the presence or absence of bacteremia (P ¼ 0.28) (Figure 4a) . However, the presence of bacteremia did delay platelet recovery (Figure 4b ). The time required for 90% of patients to achieve 50 000 platelets/mL was 21 days for patients without bacteremia and 33 days for patients with bacteremia; this suggests a significant delay in platelet recovery in a subset of these patients (Po0.001), even though the median time to engraftment was similar (15.5 and 14.5 days, respectively) for patients with and without bacteremia. patients who did and did not receive filgrastim. Kaplan-Meier curves demonstrating the proportion of patients who achieved platelet engraftment (platelet count 450 000/mL) by 1 day after transplant (P ¼ 0.12).
Discussion
The use of filgrastim to promote recovery of neutrophils has been repeatedly validated in SCT. 17 However, there have been major changes in supportive care since the first randomized trial was published in 1991. 2 At that time, the source of stem cells was BM and not peripheral blood. Determination of the adequacy of stem cell reinfusion was based on BM mononuclear cell counts per kilogram because CD34 þ cell enumeration was not widely available. Subsequently, it has been shown that mononuclear cell counts correlate poorly with CD34 þ cells; hence, the true number of infused stem cells in early studies is not well known. 18, 19 At the time of earlier studies, fluoroquinolone antibiotic prophylaxis was not available. Ciprofloxacin was not approved until 1987, and triazole antifungal antibiotics, such as ketoconazole and fluconazole, were not introduced until 1990. In the first report, 2 no antifungal prophylaxis was provided, and the protocol called for the introduction of amphotericin B for persistent febrile neutropenia. Antiviral guanosine nucleoside analogs such as acyclovir and valacyclovir were not routinely used until 1988. Therefore, the value of growth factors must be reevaluated in the light of current supportive care. In the original publication, 2 use of recombinant sargramostim resulted in fewer infections, earlier neutrophil recovery (19 days with sargramostim vs 26 days without) and decreased length of hospitalization (27 days vs 33 days). However, these outcomes are clearly not comparable to recent outcomes because of the differences between the earlier methods and the current strategy used in the modern era; this, therefore, justifies a reevaluation of the technique.
Our findings of neutrophil recovery in a median of 12.5 and 13.5 days with and without filgrastim, respectively, and median hospital stay of 3.5 and 0 days, respectively, reflect the advances in stem cell procurement and supportive care. In a 1992 study of patients with non-Hodgkin's lymphoma, the neutrophil count reached 500/mL at a median of day 14 in patients using growth factor, compared with day 21 with placebo. 3 Hospitalization was reduced from 28 to 23 days with use of growth factor. In that study, no difference was observed in fever, number of infections or antibiotic administration between the two groups. 3 A British National Lymphoma Trial using growth factor resulted in an ANC of 500/mL at 14 days, vs 20 days in controls, with no difference in platelet recovery, number of positive blood cultures, days of fever or days on parenteral antibiotics. 4 Therefore, published studies from 18 years ago validating the use of WBC growth factors cannot be used as the justification for their continued use because results without growth factors in the current decade suggest that clinically relevant outcomes are not affected. It is recognized that the use of PBSCs enhances engraftment when compared with BM. Although BM was used in the studies performed 20 years ago, marrow is an infrequent source of cells today; therefore, the value of posttransplant WBC growth factors would be expected to decrease.
Reported adverse effects of growth factor administration typically include fatigue, bone pain, low-grade fever, engraftment syndrome and capillary leak syndrome. In an assessment of the toxicity of filgrastim on normal volunteers, adverse events included bone pain, with 6% experiencing grade 3-4 toxicities and 0.6% having serious and unexpected toxicity, possibly related to the rapid increase in WBCs with growth factor stimulation and cytokine-induced noncardiogenic pulmonary edema. 10 Avoidance of these adverse effects by eliminating the use of growth factors would therefore be beneficial to patients.
The current study shows the feasibility of safe SCT without the use of growth factors to promote more rapid neutrophil engraftment. Previous reports of factors that predict engraftment include the CD34 þ stem cell dose, sex of the patient and previous therapy with an alkylating agent. 20, 21 The CD34 þ cell dose did affect engraftment in our study; platelet engraftment was clinically slower (by 3 days) and neutrophil engraftment was delayed (by 2 days) in patients who had an infusion of less than 3 Â 10 6 CD34 þ cells/kg, compared with those who were infused with greater than that number, although only 4% of patients had less than 3 Â 10 6 CD34 þ cells/kg infused.
Questions may be raised as to the adequacy of using 500 neutrophils/mL as an end point for quantifying the risk of infection. When the risk of febrile neutropenia was first defined in patients with leukemia, the neutrophil count was determined by taking the WBC count, measured in an automated manner, and multiplying it by the percentage of neutrophils identified on a peripheral blood film on manual inspection by a technologist. Frequently, these blood films contained fewer than 10 white cells on an entire smear, and the extent of variation could be substantial. In many of these situations, it would be difficult to distinguish 400 neutrophils from 50 neutrophils because of variation in the measurement technique. Today, neutrophils are directly measured by flow, and regular quantification of 100 neutrophils/mL is easily obtained. It is therefore unresolved whether the actual threshold for infection is a neutrophil count less than 500/mL. Our own anecdotal experience suggests that fever dissipates at the first appearance of circulating neutrophils and not necessarily at a level of 500/ mL. As a consequence, even the end point used for growth factor therapy efficacy is uncertain using modern technologies. In our study, we showed that it is feasible and reasonable to withhold growth factor administration after SCT. The practice of not administering growth factor after stem cell infusion is standard in European countries. [22] [23] [24] [25] This study has several limitations. The groups were not contemporaneous, in that the patients who received filgrastim underwent transplant before April 2008. Continuous improvement in supportive care and improved experience of physicians caring for these patients may result in improved outcomes; therefore, a bias is always present when comparing a more recent cohort with a historical cohort. Nevertheless, the patients who did not receive filgrastim had a lower CD34 þ cell dose infused, had a lower albumin level and higher international stage. Despite these factors, the need for hospitalization decreased without the use of filgrastim, with no adverse effects on bacteremia rates. In this study, more than half of the patients did not spend a night in the hospital. We also demonstrate that the presence of bacteremia seems to be directly related to delayed platelet engraftment. An outpatient transplant program similar to that used at Mayo Clinic may not be a feasible option for many transplant centers in densely populated urban areas. In many centers, these patients would be hospitalized, which may potentially affect the decision about whether to adopt the practice of not using filgrastim, as advocated by our group. Our ability to administer antibiotics parenterally every 12 h on an outpatient basis to febrile neutropenic patients allows for decreased utilization of hospital beds. If this is not an option, more rapid engraftment (1 day in our series) using filgrastim may be more desirable if it shortens hospitalization time, which it did not in our retrospective series.
We conclude that growth factor administration is not required for a safe outcome after SCT for multiple myeloma. It is reasonable to estimate that programs that begin filgrastim on day þ 5 and continue it until the third day of neutrophil engraftment will administer approximately 10 doses. As of 26 January 2010, http://drugstore. com listed the retail price of 10 syringes of 480 mcg filgrastim at $4621.83. Avoidance of filgrastim would result in substantial cost savings when multiplied across the 10 000 patients annually who undergo transplant for multiple myeloma in the United States. The price for a single dose of pegfilgrastim 26 was $3526.88 and still adds substantial cost to the procedure without a clear benefit, given the use of modern antibiotics, outpatient management and PBSCs. Finally, withholding growth factor potentially decreases the number and severity of some of the fluid-related complications after transplant, such as acute respiratory distress syndrome, allergic reactions, alveolar hemorrhage and, rarely, splenic rupture. 27 
